New Epidiolex(R) (CBD) Data Accepted for Presentation at the 69th Annual Meeting of the American Epilepsy Society
November 25 2015 - 9:00AM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the
Company"), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, today announced that
seven abstracts related to GW programs have been selected for
presentation at the upcoming 69th Annual Meeting of the American
Epilepsy Society including data from the physician-led Epidiolex®
(cannabidiol or CBD) expanded access program. The meeting will be
held December 4-8 in Philadelphia, PA.
"We are pleased to see a significant number of abstracts related
to Epidiolex at this year's Annual Meeting for the American
Epilepsy Society and believe this reflects the importance of this
program within the epilepsy community," stated Justin Gover, GW's
Chief Executive Officer. "The new data disclosed in these abstracts
from the Epidiolex expanded access program continues to reinforce
and support the encouraging signals of efficacy and safety
consistent with previous data disclosures. Our four pivotal Phase 3
trials of Epidiolex are now in their advanced stages and we look
forward to data from these trials next year."
Epidiolex is an oral formulation of pure plant-derived CBD. GW
is undertaking a formal development program for Epidiolex in
severe, drug-resistant childhood epilepsy syndromes which include
two pivotal Phase 3 trials of Epidiolex in Dravet syndrome and two
pivotal Phase 3 trials of Epidiolex in Lennox-Gastaut syndrome. A
Phase 3 trial in Tuberous Sclerosis Complex is due to commence
shortly.
The following is a list of Epidiolex related posters and their
presentation times. Additional information on the American Epilepsy
Society and presentations at the annual meeting can be found online
at www.aesnet.org.
|
Late-Breaking
Abstracts |
Poster Number |
Title and Presentation Time |
3.397 |
Efficacy and Safety of Epidiolex
(Cannabidiol) in Children and Young Adults with Treatment-Resistant
Epilepsy: Update from the Expanded Access Program |
|
Poster Session 3: Monday, Dec 7, 8:00
am - 2:00 pm |
3.403 |
Cannabidiol (CBD) Treatment of Refractory
Epilepsy in Tuberous Sclerosis Complex (TSC) |
|
Poster Session 3: Monday, Dec 7, 8:00am
- 2:00 pm |
3.404 |
Cannabidiol Treatment of Refractory Epileptic
Spasms: An Open Label Study |
|
Poster Session 3: Monday, Dec 7, 8:00am
- 2:00 pm |
|
|
Original Abstracts |
Poster Number |
Title and Presentation Time |
2.164 |
Cannabidiol in Genetic Refractive Epilepsy in
Dravet and Non-Dravet Cases |
|
Poster Session 2: Sunday, Dec 6, 8:00
am - 4:00 pm |
2.296 |
Long-term Efficacy and Tolerability of Add-On
Cannabidiol for Drug-Resistant Pediatric Epilepsies |
|
Poster Session 2: Sunday, Dec 6, 8:00
am - 4:00 pm |
2.375 |
Socioeconomic Characteristics of Patients in
the Alabama Study of Cannabidiol (CBD) Use to Treat Epilepsy |
|
Poster Session 2: Sunday, Dec 6, 8:00
am - 4:00 pm |
3.034 |
Assessment of the Anticonvulsant Effects and
Tolerability of GW Pharmaceuticals' Cannabidiol in the
Anticonvulsant Screening Program |
|
Poster Session 3: Monday, Dec 7, 8:00
am - 2:00 pm |
|
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex®, which is approved for the
treatment of spasticity due to multiple sclerosis in 27 countries
outside the United States. GW is advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex®,
which is in Phase 3 clinical development for the treatment of
Dravet syndrome and Lennox-Gastaut syndrome and which is also
expected to enter Phase 3 clinical trials in the treatment of
Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, type 2 diabetes, and schizophrenia. For further
information, please visit www.gwpharm.com.
CONTACT: GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway
+ 44 20 3727 1000
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024